Qiagen N V 's Quick Ratio

QGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Quick Ratio deteriorated to 1.57 below Qiagen N V 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 37 other companies have achieved higher Quick Ratio than Qiagen N V in forth quarter 2023. While Quick Ratio total ranking in the forth quarter 2023 has deteriorated compared to the prior quarter from 0 to 659.

Explain Quick Ratio?
How much Cash & cash equivalents QGEN´s has?
What are QGEN´s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

QGEN Quick Ratio	(Dec 31 2023) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2022) IV. Quarter
Y / Y Current Liabilities Change	37.65 %	37.65 %	37.65 %	37.65 %	-48.54 %
Y / Y Cash & cash equivalent Change	-25.42 %	-25.42 %	-25.42 %	-25.42 %	33.13 %
Quick Ratio MRQ	1.57	1.57	1.57	1.57	2.9
QGEN's Total Ranking	# 659	# 0	# 0	# 0	# 1217
Seq. Current Liabilities Change	0 %	0 %	0 %	37.65 %	0 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	-25.42 %	0 %

New: More QGEN's historic Quick Ratios >>

Quick Ratio forth quarter 2023 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 38
Healthcare Sector	# 215
Overall Market	# 659

Quick Ratio Statistics
High	Average	Low
3.13	1.64	0.57
(Dec 31 2017)		(Dec 31 2011)

Financial Statements
Qiagen N V 's Current Liabilities	$ 672 Millions	Visit QGEN's Balance sheet
Qiagen N V 's Cash & cash equivalent	$ 1,058 Millions	Visit QGEN's Balance sheet
Source of QGEN's Sales		Visit QGEN's Sales by Geography

Cumulative Qiagen N V 's Quick Ratio

QGEN's Quick Ratio for the trailling 12 Months

QGEN Quick Ratio	(Dec 31 2023) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2022) IV. Quarter
Y / Y Current Liabilities TTM Growth	37.65 %	37.65 %	37.65 %	37.65 %	-48.54 %
Y / Y Cash & cash equivalent TTM Growth	-25.42 %	-25.42 %	-25.42 %	-25.42 %	33.13 %
Quick Ratio TTM	1.57	1.83	2.13	2.49	2.9
Total Ranking TTM	# 974	#	#	#	# 1641
Seq. Current Liabilities TTM Growth	0 %	0 %	0 %	37.65 %	0 %
Seq. Cash & cash equivalent TTM Growth	0 %	0 %	0 %	-25.42 %	0 %

Quick ratio ranking by company, industry and sector >> Back to QGEN Financial Strength Comparisons >> Go to Compare QGEN Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchange in Current Liabilities in the IV Quarter 2023 to $672.13 millions, cumulative Quick Ratio decreased to 1.57 above the QGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 86 other companies have achieved higher Quick Ratio than Qiagen N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 0 to 466.

Explain Quick Ratio?
How much Cash & cash equivalents QGEN´s has?
What are QGEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 87
Healthcare Sector	# 627
Within the Market	# 659

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.13	1.42	0.7
(Dec 31 2017)		(Dec 31 2021)

Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2023 MRQ Cash & cash equivalent	Dec 31 2023 MRQ Current Liabilities
Cardiol Therapeutics inc	4.21	$ 26.758 Millions	$ 6.354 Millions
Recursion Pharmaceuticals Inc	4.20	$ 391.565 Millions	$ 93.171 Millions
Adverum Biotechnologies Inc	3.87	$ 96.526 Millions	$ 24.914 Millions
Sophia Genetics Sa	3.46	$ 123.251 Millions	$ 35.621 Millions
Dyadic International Inc	3.23	$ 7.263 Millions	$ 2.252 Millions
Immunocore Holdings Plc	3.22	$ 442.626 Millions	$ 137.633 Millions
C4 Therapeutics Inc	2.96	$ 126.590 Millions	$ 42.766 Millions
Cognition Therapeutics inc	2.94	$ 29.922 Millions	$ 10.169 Millions
Moderna Inc	2.85	$ 8,604.000 Millions	$ 3,015.000 Millions
Iovance Biotherapeutics Inc	2.73	$ 279.867 Millions	$ 102.529 Millions
Biocryst Pharmaceuticals Inc	2.61	$ 390.791 Millions	$ 149.988 Millions
Exelixis Inc	2.52	$ 995.302 Millions	$ 394.277 Millions
Vericel Corporation	2.39	$ 109.557 Millions	$ 45.749 Millions
Prime Medicine Inc	2.06	$ 116.213 Millions	$ 56.423 Millions
Genfit S a	2.02	$ 87.124 Millions	$ 43.098 Millions
Adaptimmune Therapeutics Plc	2.02	$ 146.938 Millions	$ 72.788 Millions
Armata Pharmaceuticals Inc	1.94	$ 13.523 Millions	$ 6.980 Millions
Meiragtx Holdings Plc	1.93	$ 129.566 Millions	$ 67.078 Millions
Innate Pharma Sa	1.78	$ 79.078 Millions	$ 44.393 Millions
Fennec Pharmaceuticals inc	1.76	$ 13.269 Millions	$ 7.532 Millions
Neurocrine Biosciences Inc	1.58	$ 1,031.600 Millions	$ 654.800 Millions
Qiagen N v	1.57	$ 1,057.782 Millions	$ 672.125 Millions
Cyclo Therapeutics Inc	1.24	$ 9.247 Millions	$ 7.457 Millions
Pluri Inc	1.21	$ 5.468 Millions	$ 4.530 Millions
Adma Biologics Inc	1.06	$ 51.352 Millions	$ 48.579 Millions
Halozyme Therapeutics Inc	1.05	$ 118.370 Millions	$ 112.494 Millions
Bio techne Corp	1.00	$ 135.652 Millions	$ 135.231 Millions
Sangamo Therapeutics Inc	0.95	$ 45.204 Millions	$ 47.731 Millions
Ladrx Corporation	0.94	$ 2.070 Millions	$ 2.201 Millions
Valneva Se	0.79	$ 141.210 Millions	$ 177.927 Millions

Date modified: 2024-03-11T21:17:11+00:00

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com